Results 201 to 210 of about 40,497 (266)

Temporal and geographical patterns of nitazene detections in drug samples and biospecimens in the United States, 2019–2024

Addiction, Volume 121, Issue 8, Page 2019-2032, August 2026.
Abstract Background and aims Nitazenes are a novel subclass of synthetic opioids that have been increasingly implicated in the United States (US) overdose crisis. Despite their growing presence in the illicit drug supply, national trends have not been systematically evaluated.
David T. Zhu, Nicole D. Fitzgerald, Joseph J. Palamar, Alex J. Krotulski   +3 more
wiley   +1 more source

Might modulation of the endocannabinoid system provide a potential dual therapeutic strategy for osteoporosis and depression?

General Psychiatry, Volume 39, Issue 4, August 2026.
Peng Wei, Pianpian Zhao, Zenghui Gu, Mengyuan Yang, David Karasik, Ching‐Lung Cheung, Houfeng Zheng   +6 more
wiley   +1 more source

The association between sleep disturbance and stimulant use: A cross‐lagged examination

Addiction, Volume 121, Issue 8, Page 2116-2126, August 2026.
Abstract Background and aims Sleep disruptions increase the risk of substance misuse. Substance use—especially stimulants—can increase acute and chronic sleep dysfunction. This study aimed to estimate the associations between sleep disturbance and stimulant use over time among participants with stimulant use disorder (StUD).
Viviana E. Horigian, Renae D. Schmidt, Daniel J. Feaster, Rui Duan, Sophia T. Gonzalez, Kathryn Hefner, Dikla Shmueli‐Blumberg, Ashley Vena, Landhing M. Moran, Chloe A. DiCamillo, Shirin Shafazand, Susan Tross, Judith Feinberg   +12 more
wiley   +1 more source

Assessments of Evoked and Spontaneous Pain Following Administration of Gabapentin and the Cannabinoid CB₂ Agonist LY2828360 in a Rat Model of Spared Nerve Injury. [PDF]

Cannabis Cannabinoid Res
Guenther KG, Crystal JD, Hohmann AG.
europepmc   +1 more source

5‐HT2A receptor agonism by tert‐leucinamide and valinamide synthetic cannabinoids: In vitro and in vivo evidence

British Journal of Pharmacology, Volume 183, Issue 16, Page 4715-4734, August 2026.
Abstract Background and Purpose New synthetic cannabinoid receptor agonists (SCRAs) are associated with severe adverse effects, including unexpected psychiatric symptoms. These compounds are mainly active through their potent agonism on the cannabinoid receptors CB1 and CB2.
Giorgia Corli, Deborah Rudin, Dino Luethi, Matthias E. Liechti, Sabrine Bilel, Matteo Marti, Henrik Green, Manuela Carla Monti, Caitlyn Norman   +8 more
wiley   +1 more source

What Do Thirty Years of Neuroimaging Research Tell Us About Recreational Cannabis Use and Brain Integrity? A Narrative Review of the Multimodal Neuroimaging Evidence to Date. [PDF]

Subst Abuse Rehabil
Murphy E, Suo C, Poudel G, Thomson H, Lorenzetti V.   +4 more
europepmc   +1 more source

Inhibition of peripheral CB1 receptors modulates food intake and metabolic efficiency in obesity independently of the gut–brain vagal axis

British Journal of Pharmacology, Volume 183, Issue 16, Page 4953-4968, August 2026.
Background and Purpose Obesity involves profound disruptions in neuronal circuits, neuroendocrine communication and the endocannabinoid system. While global blockade of cannabinoid CB1 receptors improves metabolism, its clinical use is limited by neuropsychiatric side effects.
Oriane Onimus, Camille de Almeida, Benoit Bertrand, Julien Castel, Nejmeh Mashhour, Anthony Ansoult, Serge Luquet, Giuseppe Gangarossa   +7 more
wiley   +1 more source

Refining Cannabinoid Ratios for Geriatric Pain: Methodological and Clinical Reflections on the CARE Study [Letter]. [PDF]

J Pain Res
Qiang D, Zheng C, Xu Y.
europepmc   +1 more source

Multivalent antibody‐based conjugates as new tools for tailored modulation of G protein–coupled receptors

British Journal of Pharmacology, Volume 183, Issue 16, Page 4512-4531, August 2026.
The G protein–coupled receptor (GPCR) superfamily consists of the most common targets of approved drugs. Targeting GPCRs offers appealing avenues for therapeutic development. Antibodies and their fragments, such as single‐domain antibodies (VHHs or nanobodies), have emerged as useful alternatives to small molecule pharmacophores as building blocks in ...
Shivani Sachdev, Ross W. Cheloha
wiley   +1 more source

Longitudinal neurocognitive trajectories in a large cohort of youth who use cannabis: combining self-report and toxicology. [PDF]

Neuropsychopharmacology
Wade NE, Sullivan RM, Wallace AL, Visontay R, Szpak V, Lisdahl KM, Huestis MA, Gonçalves PD, Byrne H, Mewton L, Jacobus J, Tapert SF.   +11 more
europepmc   +1 more source